Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabienne Thomas

Showing results (81-90 of 83) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 83 results.
British Journal of Cancer|January 15, 2024
Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysisGwénaël Le Teuff, Nathalie Cozic, Jean-Christophe Boyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2026
Phase I/II study of the PARP inhibitor olaparib and irinotecan in children and young adults with recurrent/refractory malignancies: Arm D of the AcSé-ESMART trialSusanne A Gatz, Pablo Berlanga, Gwénaël Le Teuff, et al.
NPJ Breast Cancer|March 21, 2026
A multi-ancestry genome-wide study of tamoxifen metabolism and breast cancer recurrenceChiea Chuen Khor, Whee Sze Ong, Elaine Hsuen Lim, et al.
Pageof 9

Showing results (81-90 of 83) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 83 results.
British Journal of Cancer|January 15, 2024
Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysisGwénaël Le Teuff, Nathalie Cozic, Jean-Christophe Boyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2026
Phase I/II study of the PARP inhibitor olaparib and irinotecan in children and young adults with recurrent/refractory malignancies: Arm D of the AcSé-ESMART trialSusanne A Gatz, Pablo Berlanga, Gwénaël Le Teuff, et al.
NPJ Breast Cancer|March 21, 2026
A multi-ancestry genome-wide study of tamoxifen metabolism and breast cancer recurrenceChiea Chuen Khor, Whee Sze Ong, Elaine Hsuen Lim, et al.
Pageof 9